Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.
Evogene Ltd. reports developments as a computational chemistry company focused on generative design of small molecules for pharmaceutical and agricultural applications. Its recurring updates center on ChemPass AI™, a proprietary generative AI platform used to explore chemical space and optimize small-molecule candidates across multiple parameters.
Company news also covers financial results, strategic refocusing around ChemPass AI™, collaborations in drug discovery and ag-chemical development, and subsidiary activity. Reported subsidiary themes include Casterra's castor seed varieties and castor farming systems for bio-based industries, AgPlenus work on novel herbicides and fungicides, Biomica microbiome-based therapeutics, and Nasdaq listing-compliance matters for EVGN ordinary shares.
Evogene Ltd. (NASDAQ: EVGN) reported its Q1 2022 financial results, showing revenues of $237K, a decline from $333K in Q1 2021. The company maintains a strong cash position of approximately $45 million. R&D expenses increased to $5.6 million from $4.3 million year-over-year, primarily due to ongoing clinical preparations. The net loss for the quarter was $9.1 million, up from $7.1 million in Q1 2021. Significant milestones include Biomica's positive pre-clinical results for BMC333 and the initiation of its first-in-human study. Lavie Bio's product 'result™' has shown potential yield improvements for growers amidst rising wheat prices.
Biomica Ltd., a biopharmaceutical subsidiary of Evogene (NASDAQ: EVGN), will present its research at the 2022 ASCO Annual Meeting in Chicago from June 3-7, 2022. The presentation, titled "A rationally designed live bacterial consortium for the potentiation of immune checkpoint therapy in solid tumors," has been selected for a poster session and the GRASP Advocate Choice Award. Dr. Corinne Maurice-Dror will present on June 5, 2022. Biomica is focused on microbiome-based therapeutics for antibiotic resistance and immuno-oncology.
Biomica Ltd., a subsidiary of Evogene (NASDAQ: EVGN), will present at Digestive Disease Week (DDW) 2022 in San Diego, California, from May 21-24. Professor Yehuda Ringel, Biomica's CSO, is scheduled to speak on May 22 from 4:00 PM to 5:30 PM PDT about the anti-inflammatory effects of a live bacterial consortium for treating Inflammatory Bowel Disorders (IBD). This presentation will share findings from pre-clinical research on microbiome-based drug development. Biomica focuses on microbiome therapeutics for gastrointestinal disorders and bacterial resistance.
Lavie Bio Ltd., a subsidiary of Evogene (NASDAQ: EVGN), reports strong demand for its bio-inoculant result™ during the 2022 growing season, successfully selling its entire production to U.S. customers. This demand is driven by rising global wheat prices due to shortages exacerbated by the Russia-Ukraine conflict. Field trials indicate result™ can enhance yields by 3-4 bushels per acre, translating to an additional $30-40 in revenue per acre for farmers. The company plans to increase production for the 2023 season and expand sales to Canada and Europe.
Evogene Ltd. (NASDAQ: EVGN) announced it will release its financial results for Q1 2022 on May 26, 2022. The conference call to discuss these results will take place at 09:00 AM ET, featuring Dr. Elran Haber from Biomica Ltd. Evogene focuses on using computational biology to enhance life-science product development through its innovative technologies: MicroBoost AI, ChemPass AI, and GeneRator AI. The company aims to reduce costs and development time while increasing success rates in product development.
Biomica, a biopharmaceutical company and subsidiary of Evogene (NASDAQ: EVGN), has entered a collaboration with Sheba Medical Center to research Inflammatory Bowel Disease (IBD). This partnership aims to explore microbiome profiles in IBD patients to better understand the condition and develop innovative therapies. The global IBD treatment market was valued at USD 19.2 billion in 2020. Biomica plans to scale up and produce initial clinical batches of its product candidate, BMC333, following positive pre-clinical results.
Evogene Ltd. (NASDAQ: EVGN) announced its participation in the Jefferies Virtual Synthetic Biology Week from March 21-25, 2022. Chief Product Officer, Dr. Nir Arbel, will engage in a fireside chat on March 23, 2022, at 10 am ET and will be available for one-on-one meetings with investors on March 24, 2022. Evogene aims to transform life-science product development through its innovative technological engines: MicroBoost AI, ChemPass AI, and GeneRator AI. These engines focus on microbiome therapeutics, medical cannabis, ag-chemicals, and ag-biologicals.
Evogene Ltd. (NASDAQ: EVGN) reported its financial results for Q4 and full year 2021, showing an operating loss of $31 million, up from $24.8 million in 2020. The company maintains a solid cash position of approximately $54 million, aiding its subsidiaries in product development. Key achievements include Biomica's clearance for a phase I immuno-oncology study and Canonic's commercial sales of cannabis products. Looking ahead, Evogene targets 2022 milestones such as launching new products and expanding R&D activities.
Evogene Ltd. (NASDAQ: EVGN) announced its participation in the upcoming World Agri-Tech Innovation Summit on March 22-23, 2022, in San Francisco. This summit has established itself as a pivotal event for the global agtech ecosystem, bringing together growers, agribusiness leaders, technology pioneers, and investors. Key executives from Evogene, including CEO Ofer Haviv and other senior management from its subsidiaries, will be present to explore partnerships and insights. Evogene leverages cutting-edge computational biology to innovate in various life-science industries.
Evogene Ltd. (NASDAQ: EVGN) announced its participation in the 34th Annual ROTH Conference in Dana Point, California, from March 13-15, 2022. CEO Ofer Haviv will host a live fireside chat on March 15 at 12pm PT, along with one-on-one meetings with investors. The conference includes various presentations and panels, attracting institutional investors and analysts. Evogene's innovative technologies, such as MicroBoost AI and GeneRator AI, are focused on life-science product development.